| Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. | |
| | |
MedLine Citation:
|
PMID: 21892858 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Objective: To evaluate clinical and economic outcomes in patients with type 2 diabetes mellitus (T2DM) who failed oral anti-diabetic drug (OAD) therapy and initiated either insulin glargine with disposable pen (GLA-P) or exenatide BID (EXE). Research design and methods: This retrospective study used data from a large US-managed care claims database and included adult T2DM patients initiating treatment with GLA-P or EXE in 2007 or 2008. Propensity score matching was used to control observed baseline differences between treatment groups. Primary study end-points included treatment persistence, A1C, healthcare utilization, and healthcare costs during the 1-year follow-up period. Results: Two thousand three hundred and thirty nine patients were included in the study (GLA-P: 381; EXE: 1958); 626 patients were in the 1:1 matched cohort (54% male; mean age: 54 years; mean A1C: 9.2%). At follow-up, patients in the GLA-P group were significantly more persistent in treatment than EXE patients (48% vs 15% in persistence rate and 252 vs 144 days in persistence days; both p < 0.001). GLA-P patients also had significantly lower A1C at follow-up (8.02% vs 8.32%; p = 0.042) and greater A1C reduction from baseline (-1.23% vs -0.92%; p = 0.038). There were no significant differences in claims-based hypoglycemia rates and overall diabetes-related healthcare utilization and cost. Limitations: Since this was a retrospective analysis, causality of treatment benefits cannot be established. The study was specific to two treatments and may not generalize to other models of insulin administration. Some of the results, although statistically significant, may not be found clinically important. Conclusions: In a real-world setting among T2DM patients who failed to achieve or sustain glycemic goal with OADs, initiation of GLA-P instead of EXE may be a more effective option because it was associated with greater treatment persistence, greater A1C reduction without a significantly higher rate of hypoglycemia, and similar healthcare costs. |
| | |
Authors:
|
Onur Baser; Wenhui Wei; Erdem Baser; Lin Xie |
Related Documents
:
|
11151768 - Quantitative trait loci for obesity and insulin resistance (nob1, nob2) and their inter... 12882908 - Insulin-stimulated protein kinase c lambda/zeta activity is reduced in skeletal muscle ... 17341558 - Reduction of elevated serum retinol binding protein in obese children by lifestyle inte... 2648798 - Circulating and excreted levels of chromium after an oral glucose challenge: influence ... 14500058 - Look ahead (action for health in diabetes): design and methods for a clinical trial of ... 9462418 - Hyperinsulinemia in relation to hypertension and other coronary risk factors in japanes... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-5 |
Journal Detail:
|
Title: Journal of medical economics Volume: - ISSN: 1941-837X ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-6 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9892255 Medline TA: J Med Econ Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
The University of Michigan , MI, USA, and STATinMED Research, Ann Arbor, MI , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Trajectory analysis of healthcare costs for patients with major depressive disorder treated with hig...
Next Document: Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related...